Involvement of Mast-Cell-Tryptase- and Protease-Activated Receptor 2-Mediated Signaling and Urothelial Barrier Dysfunction with Reduced Uroplakin II Expression in Bladder Hyperactivity Induced by Chronic Bladder Ischemia in the Rat.
bladder hyperactivity
chronic bladder ischemia
mast cell infiltration
urothelial barrier dysfunction
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
16 Feb 2023
16 Feb 2023
Historique:
received:
29
12
2022
revised:
07
02
2023
accepted:
14
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
We aimed to investigate the relationship between mast cell (MC) infiltration into the bladder with urothelial barrier dysfunction and bladder hyperactivity in a chronic bladder ischemia (CBI) rat model. We compared CBI rats (CBI group; n = 10) with normal rats (control group; n = 10). We measured the expression of mast cell tryptase (MCT) and protease-activated receptor 2 (PAR2), which are correlated with C fiber activation via MCT, and Uroplakins (UP Ia, Ib, II and III), which are critical to urothelial barrier function, via Western blotting. The effects of FSLLRY-NH2, a PAR2 antagonist, administered intravenously, on the bladder function of CBI rats were evaluated with a cystometrogram. In the CBI group, the MC number in the bladder was significantly greater (
Identifiants
pubmed: 36835398
pii: ijms24043982
doi: 10.3390/ijms24043982
pmc: PMC9966957
pii:
doi:
Substances chimiques
Receptor, PAR-2
0
Tryptases
EC 3.4.21.59
Uroplakin II
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Aging (Albany NY). 2019 Dec 16;11(24):12532-12545
pubmed: 31841119
J Comp Neurol. 1995 Dec 4;363(1):28-36
pubmed: 8682935
Low Urin Tract Symptoms. 2012 Jan;4(1):9-13
pubmed: 26676452
Am J Physiol Renal Physiol. 2002 Dec;283(6):F1200-7
pubmed: 12388410
Circ Res. 2002 Mar 8;90(4):465-72
pubmed: 11884377
Int Neurourol J. 2017 Sep;21(3):163-170
pubmed: 28954463
Am J Physiol Gastrointest Liver Physiol. 2009 Jul;297(1):G34-42
pubmed: 19423751
Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5
pubmed: 17049716
Sci Rep. 2020 Nov 16;10(1):19844
pubmed: 33199757
J Immunol. 2003 Apr 15;170(8):4296-300
pubmed: 12682265
Am J Physiol Renal Physiol. 2000 Apr;278(4):F540-53
pubmed: 10751214
J Cell Biol. 2004 Dec 20;167(6):1195-204
pubmed: 15611339
Front Pharmacol. 2017 May 11;8:259
pubmed: 28553229
Urology. 2018 Jan;111:238.e7-238.e12
pubmed: 29051005
Eur Urol. 2006 Sep;50(3):581-6
pubmed: 16519993
Neurourol Urodyn. 2014 Jan;33(1):54-8
pubmed: 24292974
J Neurosci. 2009 May 13;29(19):6124-31
pubmed: 19439590
Neurourol Urodyn. 2009;28(8):1028-33
pubmed: 19267388
Neurourol Urodyn. 2011 Jun;30(5):684-91
pubmed: 21661014
J Urol. 2005 Feb;173(2):635-9
pubmed: 15643279
Urology. 2012 Jul;80(1):225.e13-8
pubmed: 22521193
Int J Urol. 2018 Mar;25(3):298-304
pubmed: 29268303
Am J Physiol. 1998 Jun;274(6):C1429-52
pubmed: 9696685
Urology. 2002 May;59(5 Suppl 1):61-7
pubmed: 12007524
Physiol Res. 2016 Jul 18;65(3):357-67
pubmed: 27070742
Biochim Biophys Acta. 2012 Jan;1822(1):74-84
pubmed: 21496484
Neurourol Urodyn. 2011 Mar;30(3):417-20
pubmed: 21284020
Urology. 2003 Nov;62(5 Suppl 2):3-10
pubmed: 14662401
Int Braz J Urol. 2016 Mar-Apr;42(2):373-82
pubmed: 27256194
Am J Pathol. 2003 Mar;162(3):907-23
pubmed: 12598324
J Urol. 2015 Feb;193(2):706-13
pubmed: 25277818
Int Urogynecol J. 2013 Dec;24(12):2049-57
pubmed: 23670165
BJU Int. 2008 Aug;102(4):470-4
pubmed: 18476974
BJU Int. 2011 Apr;107(8):1320-5
pubmed: 20735385
Nonlinearity Biol Toxicol Med. 2005 Jan;3(1):9-21
pubmed: 19330154
Neurourol Urodyn. 2012 Jan;31(1):195-200
pubmed: 21905085
Am J Physiol. 1998 Jan;274(1):F205-14
pubmed: 9458841
Am J Physiol Renal Physiol. 2000 Jun;278(6):F867-74
pubmed: 10836974
Eur Urol. 2008 Sep;54(3):563-9
pubmed: 18423969